Florida Senate - 2001

By Senator Clary

7-1295-01 See HB A bill to be entitled 1 2 An act relating to insurance coverage for 3 investigational cancer treatments; requiring 4 coverage for investigational cancer treatments 5 under certain circumstances; specifying covered 6 costs; providing exceptions; providing criteria 7 for certain cancer trials; providing an effective date. 8 9 10 Be It Enacted by the Legislature of the State of Florida: 11 12 Section 1. Coverage for investigational cancer 13 treatments.--14 (1) An insurer that issues, delivers, amends, or renews an individual or group policy of accident and health 15 insurance in this state shall offer to the applicant or 16 17 policyholder coverage for routine patient care of insureds for participation in an approved cancer research trial, when 18 19 medically appropriate and when the insured has a terminal condition related to cancer that, according to the diagnosis 20 of the treating physician licensed to practice medicine in all 21 22 its branches, is considered life-threatening, and shall provide coverage for the patient care provided pursuant to 23 investigational cancer treatments as provided in subsection 24 (2). Coverage under this act may have an annual benefit limit 25 26 of \$10,000. 27 (2) Coverage shall include routine patient care costs, 28 including, but not limited to, costs for blood tests, X rays, 29 bone scans, magnetic resonance images, patient visits, or 30 hospital stays, or other similar costs generally incurred by the insured party in standard cancer treatment. Routine 31 1

CODING:Words stricken are deletions; words underlined are additions.

SB 1490

ts specifically shall not include the cost of
al therapies, regimens, or combinations
t of any drugs or pharmaceuticals in
an approved clinical trial; any costs
the provision of any goods, services, or
e generally furnished without charge in
an approved clinical trial program for
cer; any additional costs associated with the
goods, services, or benefits that previously
ed, paid for, or reimbursed; or any other
outine patient care costs shall specifically
s for treatments or services prescribed for
of the insured, enrollee, or physician. It is
intent of this act not to relieve the sponsor
ial program of financial responsibility for
f the program.
urposes of this act, coverage is provided
urposes of this act, coverage is provided trials that meet the following criteria:
trials that meet the following criteria:
trials that meet the following criteria: ffectiveness of the treatment has not been
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies.
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III,
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation.
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States lth and Human Services, the Director of the
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States 1th and Human Services, the Director of the tes of Health, the Commissioner of the United
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States lth and Human Services, the Director of the tes of Health, the Commissioner of the United Drug Administration, through an
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States 1th and Human Services, the Director of the tes of Health, the Commissioner of the United Drug Administration, through an new drug exemption under s. 505(1) of the
trials that meet the following criteria: ffectiveness of the treatment has not been ive to established therapies. rial is under clinical investigation as part ancer research trial in Phase II, Phase III, nvestigation. rial is approved by the United States 1th and Human Services, the Director of the tes of Health, the Commissioner of the United Drug Administration, through an new drug exemption under s. 505(1) of the ug, and Cosmetic Act or an investigational

CODING:Words stricken are deletions; words <u>underlined</u> are additions.

1 guidelines of the National Institutes of Health or a peer-reviewed and approved cancer research program, as defined 2 3 by the United States Secretary of Health and Human Services, conducted for the primary purpose of determining whether a 4 5 cancer treatment is safe or efficacious or has any other б characteristic of a cancer treatment that must be demonstrated 7 in order for the cancer treatment to be medically necessary or 8 appropriate. 9 (d) The trial is being conducted at multiple sites 10 throughout the state. 11 (e) The patient's primary care physician, if any, is involved in the coordination of care. 12 The results of the investigational trial will be 13 (f) submitted for publication in peer-reviewed scientific studies, 14 research, or literature published in or accepted for 15 publication by medical journals that meet nationally 16 17 recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts 18 19 who are not part of the editorial staff. These studies may include those conducted by or under the auspices of the 20 Federal Government's Agency for Health Care Policy and 21 Research, National Institutes of Health, National Cancer 22 Institute, National Academy of Sciences, Health Care Financing 23 24 Administration, and any national board recognized by the National Institutes of Health for the purpose of evaluating 25 the medical value of health services. 26 27 Section 2. This act shall take effect October 1, 2001. 28 29 30 31

CODING: Words stricken are deletions; words underlined are additions.

1	* * * * * * * * * * * * * * * * * * * *
2	HOUSE SUMMARY
3	
4	Requires individual or group health insurance policies to cover investigational cancer treatments. Specifies covered costs. Provides criteria for acceptable cancer trials. See bill for details.
5	covered costs. Provides criteria for acceptable cancer trials. See bill for details.
б	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
	4

CODING:Words stricken are deletions; words <u>underlined</u> are additions.